UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback